Telomium
Telomium is focused on developing innovative cancer immunotherapies, particularly targeting telomerase, a key enzyme involved in cellular proliferation and cancer. The company aims to reprogram the immune system to attack cancer cells by using proprietary ribonucleoprotein vaccine technologies that break immune tolerance and induce potent immune responses against tumor-specific antigens like telomerase.
Industries
Nr. of Employees
small (1-50)
Products
Ribonucleoprotein-based therapeutic vaccine candidates targeting telomerase
Therapeutic vaccine candidates using engineered protein–RNA complexes that present telomerase-derived antigens and deliver innate danger signals to reprogram immune recognition of cancer cells.
Ribonucleoprotein-based therapeutic vaccine candidates targeting telomerase
Therapeutic vaccine candidates using engineered protein–RNA complexes that present telomerase-derived antigens and deliver innate danger signals to reprogram immune recognition of cancer cells.
Services
Ribonucleoprotein vaccine R&D and preclinical development
Research and preclinical development services focused on engineered protein–RNA vaccine constructs designed to induce potent cellular immunity and break immune tolerance to self-antigens.
Ribonucleoprotein vaccine R&D and preclinical development
Research and preclinical development services focused on engineered protein–RNA vaccine constructs designed to induce potent cellular immunity and break immune tolerance to self-antigens.
Expertise Areas
- Cancer immunotherapy
- Therapeutic vaccine development
- Ribonucleoprotein engineering
- Tumor-associated antigen targeting (telomerase)
Key Technologies
- Ribonucleoprotein vaccine platform
- Telomerase antigen targeting
- Dual BCR/TLR signaling modulation
- Epitope spreading induction